Stoke Therapeutics’ (NASDAQ:STOK) lock-up period will end on Monday, December 16th. Stoke Therapeutics had issued 7,891,110 shares in its initial public offering on June 19th. The total size of the offering was $142,039,980 based on an initial share price of $18.00. After the end of Stoke Therapeutics’ lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
STOK has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Stoke Therapeutics in a report on Monday. Cowen reaffirmed a “buy” rating on shares of Stoke Therapeutics in a report on Thursday, August 15th. Zacks Investment Research raised shares of Stoke Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price objective for the company in a report on Wednesday, October 16th. JPMorgan Chase & Co. dropped their price objective on shares of Stoke Therapeutics from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, December 3rd. Finally, BTIG Research initiated coverage on shares of Stoke Therapeutics in a report on Tuesday, November 12th. They set a “buy” rating and a $46.00 price objective for the company. Seven analysts have rated the stock with a buy rating, Stoke Therapeutics presently has an average rating of “Buy” and an average target price of $35.17.
Shares of NASDAQ:STOK opened at $25.37 on Wednesday. The stock has a fifty day simple moving average of $25.82. Stoke Therapeutics has a 52 week low of $19.21 and a 52 week high of $39.04.
In other Stoke Therapeutics news, major shareholder Rtw Investments, Lp bought 31,560 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were bought at an average price of $21.96 per share, for a total transaction of $693,057.60. In the last quarter, insiders purchased 205,216 shares of company stock worth $5,771,421.
A number of large investors have recently modified their holdings of STOK. Platinum Investment Management Ltd. purchased a new position in Stoke Therapeutics in the 2nd quarter worth $29,000. Strs Ohio purchased a new position in Stoke Therapeutics in the 3rd quarter worth $51,000. Victory Capital Management Inc. purchased a new position in Stoke Therapeutics in the 2nd quarter worth $73,000. Ladenburg Thalmann Financial Services Inc. purchased a new position in Stoke Therapeutics in the 2nd quarter worth $88,000. Finally, Morgan Stanley purchased a new position in Stoke Therapeutics in the 2nd quarter worth $104,000. Institutional investors own 48.61% of the company’s stock.
Stoke Therapeutics Company Profile
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.
See Also: Cash Asset Ratio
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.